



Implementation of Regulation 1107/2009, current issues and future challenges

CEUREG ,

Poznan, October 2014

Dr. Martyn Griffiths, Bayer SAS

Chairman of the ECPA Regulatory Policy Team

Content

- ▣ **Agricultural focus**
- ▣ **Endocrine Disruption**
- ▣ **Candidates for Substitution and comparative assessment**
- ▣ **Guidance documents**
- ▣ **Product authorisations**
- ▣ **Renewal of authorisations (Post-AIR)**


Agricultural focus

- ▶ **PPP Regulation designed to ensure high level of protection of both human and animal health and the environment...; **while improving agricultural production****
- ▶ **In terms of self sufficiency and land use outside EU, the EU consumers rely more on imported food**
 - Consumer choice to buy local will not help if the solutions for fruit and veg, often minor crops, are not available
- ▶ **Regulatory process excludes experience eg monitoring data**
- ▶ **Need for the benefits to be evaluated (already case for Biocides and REACH) to support agricultural production**



Plant protection: Trend in market introduction...

Figure 5: *Agrochemical Active Ingredients in development*



Regulatory challenges in 1107/2009

Issue	Regulation date	Actual date
Minor use report (Article 51.9)	14-DEC-2011	05-2014
Candidates for Substitution (80.7)	14-DEC-2013	2015 ?
Endocrine Disruption (Annex II, 3.6.5)	14-DEC-2013	2016 ?
Data requirements for Safeners and Synergists (Article 26)	14-DEC-2014	Postponed to 2018
Report on functioning of regulation (82)	14-DEC-2014	2016 ?



ED: Key issues

- Support for risk based approach
- Criteria could severely reduce PPPs availability in EU
 - ***Good input into the impact assessment will be vital!!***
- Application of interim criteria
 - C2 & R2: should not trigger 'cut-off' when adverse effect is not mediated via endocrine MOA



ED regulation in the EU



Horizontal ED criteria for all sectors



Pesticides

Hazard-based cut-off

Limited derogations possible

ED criteria: proposal by December 2013



Biocides

Hazard-based cut-off

Derogations possible

ED criteria: adoption by December 2013



REACH

ED may be SVHC

Authorisation based on risk assessment

ED criteria: no legal requirements

 **Harmonized criteria, but consequences differ**

Looking at the potential impact...

Potential impact of the ED criteria is extremely high

- Triazole family identified as being at risk
- *What could that mean?*

Top Ten Products, Poland, Sugarbeet, Fungicides (2011)

Brand	Net Area (000 ha)	Value (€m)
Duett Ultra	105.51	
Eminent 125 SL	9.05	
Alert	11.94	
Yamato	8.63	
Tebu 250 EW	9.34	
Topsin M 500 SC	6.72	
Orius 25 EW	5.76	
Optan 183 SE	2.52	
Horizon	2.94	
Moderator 303 SE	2.39	
Top Ten Total	164.80	2.78
Grand Total	369.72	2.90
Top Ten %	45%	96%

Key:

No longer authorised

Contains triazoles

Unaffected by ED

Candidates for Substitution

75 substances out of approx 400

- many more than envisaged as pragmatic (10%)
- equates to 40% of products subject to C. Assessment
- Multiple assessment with multiple review Post-AIR

Number a.s. could grow as substances are reviewed

Need for clear communication from Commission and MS authorities

- substances already approved in EU after passing through one of most stringent reg system

Comparative Assessment

- ▶ Will start from **summer 2015?** with the product re-authorisations (post-AIR2)
- ▶ Significant additional workload at a time when resources are stretched to the limit
- ▶ Pragmatic approach required to maintain farmers tool box
 - maintain 4 modes of action for each solution
 - safeguard solutions for minor uses




Scientific Guidance Documents: Relevance for risk assessment

Need to ensure process for new guidance consider:

- Relevance of risk assessment scenarios
- Screening capacity of the risk assessment
- Testing needs and guideline availability

Need for a clear mandate from Commission

Involve end users


- Regulatory risk assessors
 - Industry risk assessors
- 

Implementation of GD

- Define realistic implementation timelines on the basis of testing capacity
- Plan feedback on the guidance document and adjustments
- Testing phase before full implementation would be a positive step***



ECPA Survey on MS Capacity 2015



Zonal process: what has been achieved so far?

South Zone

- Established ways of working
- Agreed how to manage north zone residue data for applications including FR
- Improvements in resourcing (fees to agencies)

Central Zone

- UK CRD harmonisation initiatives
- NL Ctgb Tour of Directors
- CZSC list of agreements
- Increase in resources in some countries
- Review of working practices between MSs (pilots)

Interzonal

- dRR Workgroup could improve harmonisation
- Post Approval Issues Group – facilitating ways of working across EU
- Indications of increased willingness to mutually recognise in some countries



The Key Outstanding Issues to be Resolved

- **Increase resources to meet the demands of the regulation**
- **Remove the national requirements (technical and procedural)**
- **Increase zonal and interzonal co-operation**
 - Zonal Helpdesks to co-ordinate the work and improve efficiency
- **dRR quality**
- **Reconsideration of Article 43**
- **Article 75(3) requires MSs to ensure Authorities have sufficient resources**




Renewal program: Key concerns

- Challenging timelines for evaluation (30 months) of actives
 - AIR1 significant delays
 - AIR2 also significant delays
- Timeline for Article 43 is not manageable
- A Specific PPP should only be **reviewed once**, and not after the approval of each active substance in the PPP
- Consequence of multiple reviews (1 before) of mixture products ->Resources of MS overloaded unnecessary

ECPA Propose a technical amendment of Article 43 only

Timeline: AIR 2 -Decision Dec 2014



Renewal of product authorisations (Article 43) : Guiding principles

- Relatively minor changes for Efficacy under Regulation 1107/2009 vs Directive 91/414
- Uniform Principles complied with and original Efficacy assessment remains valid
- **No need to resubmit original data**
- Do need updated Resistance Risk Analysis
- Guidance under development

Sue Mattock, CRD, Brighton Conference, 1st. Oct 2014

Accession to EU

- **Good preparation and implementation of 1107/2009 principles before accession**
- **Implementation in advance improves one aspect of the dossier to be approved by existing MS to EU**
- **Good example Croatia, with a program of review of products to UP before accession**



Conclusion

- ▶ **2015 will be challenging**
 - Start of comparative assessment ?
 - Progress on framework legislation for ED
 - Challenges in capacity for MS: Post-AIR2
- ▶ **Need for Action**
 - Make the zonal process work efficiently
 - Amend Article 43
- ▶ **Is agricultural production improving ?**



Thank you for your attention

martyn.griffiths@bayer.com

